Skip to main content
. 2022 Jul 23;135(12):1404–1413. doi: 10.1097/CM9.0000000000002217

Figure 2.

Figure 2

PFS in NSCLC patients with (A) liver metastasis; (B) contralateral lung metastasis; (C) adrenal metastasis; (D) bone metastasis; (E) pleural metastasis; (F) different metastatic burden; (G) brain metastasis; (H) different metastatic sites treated with first-line ICIs monotherapy. ICIs: Immune checkpoint inhibitors; NSCLC: Non-small-cell lung cancer; PFS: Progression-free survival; mPFS: Median PFS.